Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1(ERCC1)in Treatment Decision.
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 15 Nov 2012 Planned end date changed from 1 Sep 2012 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 06 Sep 2010 New trial record